09 224 61 11

Lettergrootte: a a a

Wetenschappelijke publicaties

G.J.D. Hengstman, J.L. De Bleecker, E. Feist, J. Vissing, C.P. Denton, M.N. Manoussakis, J.H. Slott, B.G.M. Van Engelen, F.H.J. van den Hoogen. Open-label trial of anti-TNF-a in dermato- en polymyositis treated concomitantly with methotrexate. Eur Neurol 2008; 59:159-163.

L.B. Goldstein, P. Amarenco, M. Lamonte, S. Gilbert, M. Messig, A. Callahan, M. Hennerici, H. Sillesen, K.M. Welch; SPARCL Investigators. Relative effects of statin therapy on stroke and cardio-vascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke 2008; 39:2444-2448

S. Chaturvedi, J. Zivin, A. Breazna, P. Amarenco, A. Callahan, L.B. Goldstein, M. Hennerici, H. Sillesen, A. Rudolph, M.A. Welch; SPARCL Investigators. Effect of atorvastatin in elderly patients with recent stroke or transient ischemic attack. Neurology 2009; 72:688-694

J-M. Léger, J.L. De Bleecker, C. Sommer, W. Robbrecht, M. Saarela, J. kamienowski, Z. Stelmasiak, O. Mielke, B. Tackenberg, A. Shebi, A. Bauhofer, O. Zenker, I.S.J. Merkies, PRIMA study investigators. Efficacy and safety of privigen in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study. J Periph Nerv Syst, 2013;18:130-140

M.E. Cudkowicz, L.H. van den Berg, J.M. Shefner, H. Mitsumoto, J.S. Mora, A. Ludolph, O. Hardiman, M.E. Bozik, E.W. Ingersoll, D. Archibald, A.L. Meyers, Y. Dong, W.R. Farwell, D.A. Kerr, EMPOWER Investigators. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomized, double-blind, phase 3 trial. Lancet Neurol 2013; 12:1059-1067

Gang Q, Bettencourt C, Machado PM, Fox Z, Brady S, Healy E, Parton M, Holton JL, Hilton-Jones D, Shieh PB, Zanoteli E, De Paepe B, De Bleecker J, Shaibani A, Ripolone M, Violano R, Moggio M, Barohn RJ, Dimachkie MM, Mora M, Mantegazza R, Zanotti S, Hanna MG, Houlden H, Muscle Study Group, International IBM Genetics Consortium. The effects of an intronic polymorphism in TOMM40 and APOE genotypes in sporadic inclusion body myositis. Neurobiol Aging 2015;36(4):1766e1-3

Lilleker JB, Vencovsky J, Wang G, Wedderburn LR, Diederichsen LP, Schmidt J, Jordan P, Benveniste O, Danieli MG, Dankó K, Thuy NTP, Vázquez-Del Mercado M, Andersson H, De Paepe B, De Bleecker J, Maurer B, Pipitone N, McHugh N, Betteridge Z, New P, Cooper RG, Ollier WE, Lamb JA, Steen Krogh N, Lundberg IE, Hector Chinoy H, and EuroMyositis contributors. The EuroMyositis Registry: An International Collaborative Tool to Facilitate Myositis Research. Annals of the Rheumatic Diseases 2018, 77(1):30-39